Iovance Biotherapeutics, Inc. (IOVA)
NASDAQ: IOVA · Real-Time Price · USD
3.380
-0.050 (-1.46%)
At close: Apr 28, 2026, 4:00 PM EDT
3.400
+0.020 (0.59%)
Pre-market: Apr 29, 2026, 7:07 AM EDT
Iovance Biotherapeutics Revenue
In the year 2025, Iovance Biotherapeutics had annual revenue of $263.50M with 60.60% growth. Iovance Biotherapeutics had revenue of $86.77M in the quarter ending December 31, 2025, with 17.75% growth.
Revenue (ttm)
$263.50M
Revenue Growth
+60.60%
P/S Ratio
5.28
Revenue / Employee
$270,258
Employees
975
Market Cap
1.39B
Revenue Chart
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Ardelyx | 407.32M |
| Immunocore Holdings | 400.02M |
| Viridian Therapeutics | 70.85M |
| Agios Pharmaceuticals | 54.03M |
| Wave Life Sciences | 42.73M |
| Precigen | 9.68M |
| Maze Therapeutics | 2.50M |
IOVA News
- 1 day ago - Iovance Biotherapeutics to Report First Quarter 2026 Financial Results and Corporate Updates on Thursday, May 7, 2026 - GlobeNewsWire
- 11 days ago - Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) - GlobeNewsWire
- 6 weeks ago - Iovance Biotherapeutics Transcript: Barclays 28th Annual Global Healthcare Conference - Transcripts
- 7 weeks ago - What's Going On With Iovance Biotherapeutics Stock On Friday? - Benzinga
- 2 months ago - Iovance Biotherapeutics Transcript: TD Cowen 46th Annual Health Care Conference - Transcripts
- 2 months ago - Iovance Biotherapeutics to Present at Upcoming Conferences - GlobeNewsWire
- 2 months ago - Iovance Biotherapeutics Explodes Over 20% — Early Trial Data Sparks Investor Frenzy - Benzinga
- 2 months ago - Iovance Biotherapeutics Earnings Call Transcript: Q4 2025 - Transcripts